Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE: BLCO) released its 2025 Sustainability Impact Report and introduced The Broader Perspective framework to guide environmental, social and governance action. The report reaffirms a Net Zero by 2050 commitment and lists 2025 accomplishments in energy, waste reduction, supplier risk registration and community programs.
Bausch + Lomb (NYSE: BLCO) announced that its ONE by ONE Recycling program has collected and recycled 119,715,074 units (724,922 pounds) of used contact lenses, lens care and eye care materials in the United States as of April 16, 2026.
The program partners with TerraCycle and donates $1 per pound for qualifying 10+ pound shipments to Optometry Giving Sight.
Bausch + Lomb (NYSE:BLCO) received FDA 510(k) clearance for the Bi-Blade+ dual-port vitrectomy cutter and an Adaptive Fluidics advanced update for the Stellaris Elite system. Bi-Blade+ increases cutting speed to 25,000 cpm, raises average vitreous flow ~25%, and, with Adaptive Fluidics, showed a 62% reduction in infusion pressure and cutter vibration in bench/animal testing.
The technologies aim to improve IOP stability, efficiency and surgical control; device use is limited to Stellaris Elite systems and carries standard surgical risks.
Bausch + Lomb (NYSE: BLCO) launched the preloaded enVista Envy full range of vision intraocular lens in Europe on April 7, 2026. The diffractive premium IOL offers continuous range of vision with high dysphotopsia tolerance, ActivSync Optic energy distribution, and the new EyeGility delivery system for smooth 2 mm incision delivery.
Clinical data: 86.1% reported little to no dysphotopsia; Canadian study showed 95.4% little to no difficulty with near vision and 93% satisfaction.
Bausch + Lomb (NYSE: BLCO) will present 45 scientific presentations and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10–13, 2026. Topics span IOLs, MIGS, dry eye therapies, osmolarity testing, excimer laser trabeculostomy and real-world outcomes.
Events include company-hosted sessions April 9–11 and multiple paper and poster presentations reporting clinical evaluations, real-world evidence and device performance across the company’s portfolio.
Bausch + Lomb (NYSE: BLCO) will release its first-quarter 2026 financial results on Wednesday, April 29, 2026, and will host a conference call and live webcast at 8 a.m. ET.
All presentation materials will be posted on the company's Investor Relations website prior to the call. Replay access will be available through May 13, 2026, with passcode 53393.
Bausch + Lomb (NYSE:BLCO) announced positive 24-month pivotal U.S. trial results for the implant-free ELIOS System for open-angle glaucoma. Key outcomes: 76% of patients achieved ≥20% unmedicated IOP reduction, mean unmedicated DIOP fell by 7.4 mmHg, and 82% were medication-free at 23 months.
The ELIOS procedure reported no intraoperative complications and a postoperative adverse event rate similar to cataract surgery. ELIOS is CE marked in Europe but has not been reviewed by the FDA in the U.S.
Bausch + Lomb (NYSE: BLCO) announced an R&D “Teach-in” webinar on March 23, 2026 at 1:30 p.m. ET covering two glaucoma programs: BL1107, a medication in development targeting vision loss plus intraocular pressure, and ELIOS™, an implant-free MIGS approach commercialized in Europe with anticipated U.S. launch in 2H 2026.
The live event will feature R&D and senior executives and will be hosted by Wells Fargo; a replay will be posted on the company Investor Relations website.
Bausch + Lomb (NYSE: BLCO) cites a new global review in Ophthalmology and Therapy showing a lifestyle-driven rise in noninfectious ocular redness from digital eye strain, dry eye, allergies and environment. The review highlights LUMIFY (brimonidine tartrate 0.025%) as a differentiated OTC option with a selective α2 mechanism, no tachyphylaxis over 29 days, and virtually no rebound redness. It also notes a preservative-free brimonidine 0.025% formulation introduced by the company in 2025 with comparable efficacy and tolerability. The paper calls for more patient education on safe OTC redness treatments.
Bausch + Lomb (NYSE: BLCO) reported Q4 2025 revenue $1.405B (up 10% reported, 7% constant currency) and FY 2025 revenue $5.101B (up 6% reported, 5% CC).
GAAP net loss was $58M Q4 and $360M FY; adjusted EBITDA was $326M Q4 and $858M FY. The company guided 2026 revenue $5.375B–$5.475B and Adj. EBITDA ex-IPR&D $1.00B–$1.05B.
Operational highlights included MIEBO Q4 sales $112M, a $1.1B dry-eye portfolio in 2025, premium IOL recovery, ongoing clinical trial recruitment, cash of $397M, and a webcast replay available through March 4, 2026.